Published in Medical Letter on the CDC and FDA, October 30th, 2005
FL "is the second most common non-Hodgkin lymphoma and generally is incurable," pathologists in the United States explained. "Reliable prognostic markers to differentiate patients who progress rapidly from those who survive for years with indolent disease have not been established."
"Most cases overexpress Bcl-2, but the pathogenesis of FL remains incompletely understood," noted C. Gulmann and colleagues working with the U.S. National Cancer Institute-Food and Drug Administration Clinical Proteomics Program. "To determine whether a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.